<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6765">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986453</url>
  </required_header>
  <id_info>
    <org_study_id>PEAK VP-00065</org_study_id>
    <nct_id>NCT00986453</nct_id>
  </id_info>
  <brief_title>PEAK PlasmaBlade 4.0 in Bilateral Breast Reduction</brief_title>
  <acronym>PRECISE</acronym>
  <official_title>A Prospective, Randomized, Controlled Study to Evaluate Use of the PEAK PlasmaBlade 4.0 in Bilateral Breast Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Surgical Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Surgical Technologies</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate the operative performance of the PEAK
      PlasmaBlade 4.0 during bilateral breast reduction; to monitor and record post-operative
      pain, adverse events and skin scarring following surgery; and compare these outcomes to the
      current standard of care (SOC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bilateral breast reduction is a surgical procedure performed to remove excess breast tissue
      from both female breasts for therapeutic or cosmetic indications. The purpose of the breast
      reduction is to decrease the weight of the breasts and restructure the breast tissue for a
      more favorable appearance. Typically, a scalpel is used for the skin incision and a
      traditional electrosurgical device is used to cut away any excess tissue.

      The PEAK PlasmaBladeâ„¢ uses pulsed radiofrequency (RF) energy and a highly-insulated
      handpiece design to enable precision cutting and coagulation at the point of application.
      The PlasmaBlade has received FDA clearance for use in plastic, general, and ear, nose, and
      throat (ENT) surgery, and has demonstrated a significantly reduced thermal injury profile in
      incised tissue compared to traditional electrosurgical devices. It is hypothesized that this
      benefit may improve the post-operative outcome of patients undergoing bilateral breast
      reduction.

      A total of forty-five (45) subjects were enrolled into the study. Forty-three (43) underwent
      bilateral breast reduction, and two (2) subjects were withdrawn prior to surgery. Enrollment
      and surgeries took place between 18 September 2009 and 12 August 2011. Potential subjects
      were screened against the inclusion and exclusion criteria of the study protocol and were
      required to provide informed consent prior to enrollment. Following enrollment, subject
      operative sites were prospectively randomized to the SOC or PlasmaBlade (PB or PEAK) study
      groups and scheduled for bilateral breast reduction. Subjects were unaware of which device
      was used on which breast. Subjects were required to attend two follow-up visits after
      surgery, approximately one and six weeks following surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Postoperative Pain</measure>
    <time_frame>0 to 10 days postoperative</time_frame>
    <safety_issue>No</safety_issue>
    <description>The difference in pain was measured by visual analog scale for 24 hours post-operatively and for 10 post-operative days twice daily between the SOC and PlasmaBlade operative sites.
Wong-Baker FACES Visual Analog Scale, 0 (no hurt) to 10 (hurts worst). The results represent the mean of each subject's mean pain scores over 10 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated Blood Loss</measure>
    <time_frame>Intraoperative</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative Time</measure>
    <time_frame>Intraoperative</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Tissue Removed</measure>
    <time_frame>Intraoperative</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dissection Performance</measure>
    <time_frame>Intraoperative</time_frame>
    <safety_issue>No</safety_issue>
    <description>Amount of tissue (g) removed over time (min)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Macromastia</condition>
  <arm_group>
    <arm_group_label>PlasmaBlade arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PEAK PlasmaBlade</intervention_name>
    <description>The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.</description>
    <arm_group_label>PlasmaBlade arm</arm_group_label>
    <other_name>PlasmaBlade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Traditional Electrosurgery with scalpel</intervention_name>
    <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Scalpel</other_name>
    <other_name>Electrosurgery</other_name>
    <other_name>SOC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 20 and 60

          2. Physically healthy, stable weight, non-smoker

          3. Desiring bilateral breast reduction

          4. Subject must understand the nature of the procedure and provide written informed
             consent prior to the procedure.

          5. Subject must be willing and able to comply with specified follow-up evaluations.

          6. Female subjects must either be no longer capable of reproduction, or taking
             acceptable measures to prevent pregnancy during the study, and have a negative
             pregnancy test prior to participation in the study.

        Exclusion Criteria:

          1. Age younger than 20 or greater than 60 years old

          2. Anticoagulation therapy which cannot be discontinued

          3. Smoking (any kind)

          4. Infection (local or systemic)

          5. Cognitive impairment or mental illness

          6. Severe cardiopulmonary deficiencies

          7. Known coagulopathy

          8. Immunocompromised

          9. Prior history of breast cancer

         10. Kidney disease (any type)

         11. Currently taking any medication known to affect healing

         12. Subjects who are status-post gastric banding or gastric bypass

         13. Currently enrolled in another investigational device or drug trial

         14. Unable to follow instructions or complete follow-up
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhay Gupta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gupta Plastic Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Howard Rosenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Accent on Aesthetics Plastic Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Downey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Susan Downey, MD, FACS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Larry Pollack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Del Mar Plastic Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hooman Soltanian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Cleveland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence St. Joseph's</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Verdugo Hills Hospital</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Camino Hospital</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-City Medical Center</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Outpatient Pavilion</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rancho Bernardo Surgery Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 29, 2012</lastchanged_date>
  <firstreceived_date>September 28, 2009</firstreceived_date>
  <firstreceived_results_date>November 29, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Reduction</keyword>
  <keyword>PlasmaBlade</keyword>
  <keyword>Electrosurgery</keyword>
  <keyword>PEAK Surgical</keyword>
  <keyword>Medtronic Advanced Energy</keyword>
  <keyword>Medtronic</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects' individual breasts were prospectively randomized to the standard of care or PEAK PlasmaBlade.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Total Study Population</title>
          <description>Subjects' individual breasts were prospectively randomized to the standard of care or PEAK PlasmaBlade.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Study Population</title>
          <description>Subjects' individual breasts were prospectively randomized to the standard of care or PEAK PlasmaBlade.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="45"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="41.12" spread="14.20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="45"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="45"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Pain</title>
        <description>The difference in pain was measured by visual analog scale for 24 hours post-operatively and for 10 post-operative days twice daily between the SOC and PlasmaBlade operative sites.
Wong-Baker FACES Visual Analog Scale, 0 (no hurt) to 10 (hurts worst). The results represent the mean of each subject's mean pain scores over 10 days.</description>
        <time_frame>0 to 10 days postoperative</time_frame>
        <safety_issue>No</safety_issue>
        <population>Two subjects were removed from the analysis of secondary variables owing to protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PEAK PlasmaBlade</title>
            <description>The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC)</title>
            <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of breasts analyzed</title>
            <units>breasts</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Postoperative Pain</title>
            <description>The difference in pain was measured by visual analog scale for 24 hours post-operatively and for 10 post-operative days twice daily between the SOC and PlasmaBlade operative sites.
Wong-Baker FACES Visual Analog Scale, 0 (no hurt) to 10 (hurts worst). The results represent the mean of each subject's mean pain scores over 10 days.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.47" spread="2.05"/>
                  <measurement group_id="O2" value="4.66" spread="2.08"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.4697</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Blood Loss</title>
        <time_frame>Intraoperative</time_frame>
        <safety_issue>No</safety_issue>
        <population>Two subjects were removed from the analysis of secondary variables owing to protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PEAK PlasmaBlade</title>
            <description>The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC)</title>
            <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of breasts analyzed</title>
            <units>breasts</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Estimated Blood Loss</title>
            <units>mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56.59" spread="48.44"/>
                  <measurement group_id="O2" value="64.27" spread="34.23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.1470</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Operative Time</title>
        <time_frame>Intraoperative</time_frame>
        <safety_issue>No</safety_issue>
        <population>Two subjects were removed from the analysis of secondary variables owing to protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PEAK PlasmaBlade</title>
            <description>The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC)</title>
            <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of breasts analyzed</title>
            <units>breasts</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Operative Time</title>
            <units>minutes</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37.40" spread="15.52"/>
                  <measurement group_id="O2" value="41.55" spread="11.61"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0428</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Tissue Removed</title>
        <time_frame>Intraoperative</time_frame>
        <safety_issue>No</safety_issue>
        <population>Two subjects were removed from the analysis of secondary variables owing to protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PEAK PlasmaBlade</title>
            <description>The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC)</title>
            <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of breasts analyzed</title>
            <units>breasts</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Amount of Tissue Removed</title>
            <units>g</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="685.92" spread="347.08"/>
                  <measurement group_id="O2" value="649.18" spread="322.07"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0776</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dissection Performance</title>
        <description>Amount of tissue (g) removed over time (min)</description>
        <time_frame>Intraoperative</time_frame>
        <safety_issue>No</safety_issue>
        <population>Two subjects were removed from the analysis of secondary variables owing to protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PEAK PlasmaBlade</title>
            <description>The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC)</title>
            <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of breasts analyzed</title>
            <units>breasts</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Dissection Performance</title>
            <description>Amount of tissue (g) removed over time (min)</description>
            <units>g/min</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19.81" spread="10.65"/>
                  <measurement group_id="O2" value="15.99" spread="7.80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0002</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PEAK PlasmaBlade</title>
          <description>The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care (SOC)</title>
          <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>Second surgery was required to evacuate the hematoma.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <description>One seroma could not be attributed to either device as the device identification field was not completed; therefore, 1 seroma was added to both groups in the tabulation.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Swain, PhD</name_or_title>
      <organization>Medtronic Surgical Technologies</organization>
      <phone>+1 (603) 294-5428</phone>
      <email>robert.e.swain@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
